anxietyOctober 26, 2026
The orexinergic-endocannabinoid interface: mechanistic and therapeutic perspectives in Alzheimer's disease, anxiety, and visceral pain
Bodke S, Shelke P, Bhatt LK
Neuropeptides
1. Neuropeptides. 2026 Oct 26;120:102665. doi: 10.1016/j.npep.2026.102665. Online ahead of print.
The orexinergic-endocannabinoid interface: mechanistic and therapeutic perspectives in Alzheimer's disease, anxiety, and visceral pain.
Bodke S(1), Shelke P(1), Bhatt LK(2).
Author information: (1)Department of Pharma
This is a plain-English summary of a peer-reviewed study indexed on PubMed. It isn't medical advice.
Read the original study →